SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

MiNK-215

INKT·MiNK Therapeutics
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
Several years away, if ever. MiNK-215 remains in preclinical research with no IND filed or clinical trial initiated. An investigational new drug (IND) application and Phase 1 trial initiation would be the next milestones, which typically require 1-2 years of additional preclinical work plus regulatory review.
Why 2/10
MiNK-215 is a preclinical-stage program with no scheduled PDUFA date, pivotal readout, or IND filing catalyst in the next ~12 months. The company's near-term value is driven by its lead asset agenT-797 (Phase 2 ARDS trial, data expected 2H2027). As a small preclinical program at a cash-constrained clinical-stage company, MiNK-215 alone is unlikely to drive a material stock move in the forecast window.
Actionable Insight NEUTRAL

MiNK-215 is a preclinical asset with no near-term binary catalyst. Watch for any IND filing or first-in-human clinical trial initiation, which could take 12-24 months. The stock's near-term value driver remains the Phase 2 ARDS trial of agenT-797 (data expected 2H2027).

Price Chart

Loading chart...

Executive Summary

MiNK-215 is an investigational, allogeneic (off-the-shelf) CAR-iNKT cell therapy from MiNK Therapeutics (INKT) that targets fibroblast activation protein (FAP) on tumor-supporting stromal cells and incorporates IL-15 for enhanced persistence. It is a preclinical-stage asset with no clinical trials initiated. Preclinical data presented at AACR 2024 and SITC 2026 (November 2026) showed senolytic activity clearing chemotherapy-resistant senescent cells and anti-tumor activity in colorectal cancer liver metastasis models. MiNK-215 is a small component of MiNK's pipeline; the company's lead program is agenT-797, currently in a randomized Phase 2 trial for acute respiratory distress syndrome (ARDS) with data expected in the second half of 2027. As a preclinical program at a cash-constrained ($7.5M) clinical-stage biotech, MiNK-215 has no near-term binary catalyst and is unlikely to drive a material stock move on its own.

How It Works

MiNK-215 is an engineered immune cell therapy. It takes donor-derived invariant natural killer T (iNKT) cells and adds two features: a homing receptor (CAR) that targets a protein called FAP found on supportive cells (fibroblasts) inside tumors, and a growth factor (IL-15) to help the cells survive longer. The therapy is given as a ready-made, off-the-shelf infusion, skipping the personalized manufacturing needed for CAR-T therapies. It is designed to break down the protective barrier tumors build and kill senescent (aged, damaged) cells that chemotherapy leaves behind.

Trial Status

MiNK-215 is in preclinical development. In vitro and in vivo preclinical data have been presented at AACR 2024 and SITC 2026 demonstrating FAP-targeted CAR activity, IL-15-enhanced persistence, and senolytic effects. No clinical trials have been initiated or registered on ClinicalTrials.gov as of November 2026.

The Two-Sided Case

▲ Bull Case4
MiNK-215 is an off-the-shelf, allogeneic cell therapy (no patient-specific manufacturing delay) with a dual mechanism: FAP-targeting CAR to attack cancer-associated fibroblasts in the tumor microenvironment, plus IL-15 armoring for persistence.
Recent SITC 2026 preclinical data showed MiNK-215 and agenT-797 act as 'living senolytics,' clearing senescent tumor cells and fibroblasts left after chemotherapy, a novel application in oncology.
Analyst consensus is strongly bullish: 7 buy/strong-buy ratings vs 1 hold, with a mean price target of $44 (371% implied upside from the $9.34 close) per HC Wainwright and B. Riley.
Vanguard Fiduciary Trust added 59% to its INKT position in Q3 2026, signaling institutional interest.
▼ Bear Case5
MiNK-215 is preclinical only; it has not entered clinical trials and faces a long, uncertain path to proof-of-concept in humans.
The company's cash position of $7.5M (as of Q3 2026) is limited and may require dilutive financing to fund both the lead program (agenT-797 Phase 2 ARDS trial) and early-stage pipeline work.
CEO Jennifer Buell sold $73K in stock on October 12, 2026, and UBS trimmed its INKT position by 70% in Q3 2026, indicating insider/institutional caution.
FAP-targeting CAR cell therapies (both CAR-T and CAR-NK) are a competitive space with multiple developers, raising the bar for differentiation.
Preclinical senolytic and anti-tumor data may not translate to clinical efficacy in humans.

Upcoming Catalysts

  • No near-term catalysts specific to MiNK-215. The program would need an IND filing and Phase 1 trial initiation to become a clinical-stage asset; no timeline has been announced.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MiNK Therapeutics PRESS-RELEASE INKT ·Originating report

Sources · 6

Hover a chip for the title
1 globenewswire.com2 morningstar.com3 markets.businessinsider.com4 fox4kc.com5 sec.gov6 seekingalpha.com